278 Background: In clinical practice, the major disadvantage of lenvatinib to treat advanced hepatocellular carcinoma (HCC) is lack a posttreatment agent that has shown clear effectiveness. Thus, establishment second-line treatment after failure an urgent issue be addressed in systemic therapy patients with HCC. The study used real-world data explore candidate drugs might appropriate as lenvati...

Osteosarcoma is a common primary malignant bone tumor in young adults presenting with back and chest pain complaints. Here, we presented rare case of osteosarcoma.